On the morning of May 17, Kong Fanpu, Director of the Drug Evaluation Center of the State Drug Administration, Gao Chenyan, Minister of the Clinical Department of Biological Products, and He Wu, Vice Minister of the Department of Biological Products Pharmacy, accompanied by Zheng Chun, Director of Drug Safety of Fujian Food and Drug Administration, and Director Li Zong of the Drug Certification Review Center, came to our company for on-site investigation and inspection. Kang Xinshan, chairman/president of the company, and Feng Yan, vice president, were warmly received and accompanied.
Mr. Kang first warmly welcomed the visiting leaders and his entourage. He visited the company's laboratory with the visiting leaders and gave a brief introduction to the operation of various functional laboratories.
Subsequently, a symposium was organized. Mr. Kang reported to the visiting leaders on the company's operation and development, R&D experiments, production and sales, focusing on the research and development achievements of the company's innovative drug projects and generic drug projects, and made suggestions and opinions on the problems existing in process control such as project declaration, registration approval and product listing.
The visiting leaders listened carefully to the report, fully affirmed the company's achievements and related work, and said that they would further improve the management of MAH based on the opinions and suggestions put forward. At the same time, it is hoped that the company will continue to strengthen research and development, improve the production process, strengthen product quality management, continue to produce in compliance, continue to ensure the quality and safety of drugs, and realize the virtuous circle of the company's development.
